Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dispersion tablets for treating and preventing upper respiratory tract infection

A technology of medicine and composition, applied in the field of dispersible tablets for the treatment and prevention of upper respiratory tract infection, to achieve the effect of improving the compliance of taking

Inactive Publication Date: 2008-01-30
BEIJING D VENTUREPHARM TECH DEV
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The invention provides a pharmaceutical composition, which solves the problems of mouthfeel and dispersion uniformity, improves the patient's taking compliance, and meets the clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Acetaminophen 150g

[0022] Chlorpheniramine Maleate 1.25g

[0023] Cloperidine Hydrochloride 6g

[0024] Pseudoephedrine Hydrochloride 15g

[0025] Caffeine 12.5g

[0026] Bromelain 16 million units *

[0027] Microcrystalline Cellulose PH101 (added inside) 100g

[0028] Microcrystalline Cellulose PH101 (additional) 100g

[0029] Calcium hydrogen phosphate 150g

[0030] Crospovidone XL-10 (internal addition) 24g

[0031] Sucralose 1g

[0032] Crospovidone XL-10 (extra) 30g

[0033] Magnesium Stearate 2g

[0034]

[0035] Made into 1000 tablets, about 605.75mg per tablet

[0036] Preparation process: the raw materials are crushed and passed through a 100-mesh sieve, the magnesium stearate is passed through a 60-mesh sieve, and the rest of the auxiliary materials are passed through a 80-mesh sieve for later use. Weigh the prescribed amount of sucralose in 60g of purified water, dissolve it as a wetting agent, and...

Embodiment 2

[0038] Acetaminophen 150g

[0039] Chlorpheniramine Maleate 1.25g

[0040] Cloperidine Hydrochloride 6g

[0041] Pseudoephedrine Hydrochloride 15g

[0042] Caffeine 12.5g

[0043] Bromelain 16 million units *

[0044] Microcrystalline Cellulose PH101 200

[0045] Calcium hydrogen phosphate 150g

[0046] Crospovidone XL-10 50g

[0047] Sucralose 1g

[0048] Micronized silica gel 4g

[0049] Magnesium Stearate 2g

[0050]

[0051] Made into 1000 tablets, about 605.75mg per tablet

[0052] Preparation process: raw materials are crushed and passed through a 100-mesh sieve, magnesium stearate and micropowdered silica gel are passed through a 60-mesh sieve, and the rest of the auxiliary materials are passed through a 80-mesh sieve for later use. Weigh the prescribed amount of sucralose in 60g of purified water, dissolve it as a wetting agent, and set aside. Weigh the paracetamol, chlorpheniramine maleate, cloperidine hydrochl...

Embodiment 3

[0054] Acetaminophen 150g

[0055] Chlorpheniramine Maleate 1.25g

[0056] Cloperidine Hydrochloride 6g

[0057] Pseudoephedrine Hydrochloride 15g

[0058] Caffeine 12.5g

[0059] Bromelain 16 million units *

[0060] Microcrystalline Cellulose PH101 (added inside) 100g

[0061] Microcrystalline Cellulose PH101 (additional) 100g

[0062] Calcium hydrogen phosphate 150g

[0063] Crospovidone XL-10 54g

[0064] Sucralose 1g

[0065] Magnesium Stearate 2g

[0066]

[0067] Made into 1000 tablets, about 605.75mg per tablet

[0068] Preparation process: the raw materials are crushed and passed through a 100-mesh sieve, the magnesium stearate is passed through a 60-mesh sieve, and the rest of the auxiliary materials are passed through a 80-mesh sieve for later use. Weigh the prescribed amount of sucralose in 60g of purified water, dissolve it as a wetting agent, and set aside. Weigh the paracetamol, chlorpheniramine maleate, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a drug compound which has good taste, contains acetaminophen, chlorpheniramine maleate, cloperastini hydrochloride, pseudoephedrine hydrochloride, caffeine and bromelain and can be dispersed uniformly and is used for curing the upper respiratory tract Infection; the invention further contains fillers, disintegrating agents, flow agents, lubricants, sweeteners and other pharmaceutical excipients, and the single dose thereof is the dispersible tablet form.

Description

technical field [0001] The invention relates to a pharmaceutical composition with good taste and uniform dispersion containing acetaminophen, chlorpheniramine maleate, cloperidine hydrochloride, pseudoephedrine hydrochloride, caffeine and bromelain for treating upper respiratory tract infection. It contains pharmaceutical excipients such as fillers, disintegrants, glidants, lubricants and sweeteners, and its single dose is in the form of dispersible tablets. Background technique [0002] Clinically, there are multiple medicines for treating upper respiratory tract infections such as colds. Antipyretic and analgesic acetaminophen, vasoconstrictor pseudoephedrine hydrochloride, antihistamine chlorpheniramine maleate, cough suppressant cloperidine hydrochloride and central stimulant caffeine. In addition, bromelain can hydrolyze celluloproteinase and casein, and after oral administration, it can improve local circulation and eliminate inflammation and edema. Bromelain can rem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/522A61K31/16A61K31/137A61K31/4402A61K31/4453A61K47/38A61K47/34A61P11/00A61P31/16A61K47/32
Inventor 席红民
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com